Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.

Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V.

Lung Cancer. 2014 Aug 5. pii: S0169-5002(14)00318-3. doi: 10.1016/j.lungcan.2014.07.018. [Epub ahead of print]

PMID:
25130084
[PubMed - as supplied by publisher]
2.

Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2014 Aug;74(2):333-40. doi: 10.1007/s00280-014-2509-6. Epub 2014 Jun 15.

PMID:
24930058
[PubMed - in process]
3.

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, Boukovinas I, Polyzos A, Georgoulias V, Souglakos J.

BMC Cancer. 2014 Apr 22;14:277. doi: 10.1186/1471-2407-14-277.

PMID:
24755296
[PubMed - in process]
Free PMC Article
4.

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.

Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S.

J Chemother. 2013 Feb;25(1):49-55. doi: 10.1179/1973947812Y.0000000050.

PMID:
23433445
[PubMed - indexed for MEDLINE]
5.

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.

Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J.

Br J Cancer. 2012 Dec 4;107(12):1932-7. doi: 10.1038/bjc.2012.509. Epub 2012 Nov 20.

PMID:
23169296
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.

Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, Kotsakis A, Agelidou M, Georgoulias V.

Lung Cancer. 2012 Jul;77(1):146-50. doi: 10.1016/j.lungcan.2012.02.002. Epub 2012 Mar 13.

PMID:
22418242
[PubMed - indexed for MEDLINE]
7.

Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.

Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D.

Ann Oncol. 2012 Feb;23(2):442-9. doi: 10.1093/annonc/mdr396. Epub 2011 Aug 25.

PMID:
21873272
[PubMed - indexed for MEDLINE]
Free Article
8.

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.

Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V.

Ann Oncol. 2011 Nov;22(11):2448-55. doi: 10.1093/annonc/mdq772. Epub 2011 Mar 10.

PMID:
21393380
[PubMed - indexed for MEDLINE]
Free Article
9.

Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer.

Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J.

Clin Cancer Res. 2011 Jan 1;17(1):165-73. doi: 10.1158/1078-0432.CCR-10-0565. Epub 2010 Nov 11.

PMID:
21071514
[PubMed - indexed for MEDLINE]
Free Article
10.

A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.

Kotsakis A, Hatzidaki D, Vamvakas L, Vardakis N, Kalykaki A, Bozionelou V, Androulakis N, Kalbakis K, Saridaki Z, Georgoulias V, Agelaki S.

Anticancer Res. 2010 Oct;30(10):4335-42.

PMID:
21036760
[PubMed - indexed for MEDLINE]
11.

Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group.

Agelaki S, Hatzidaki D, Kotsakis A, Papakotoulas P, Polyzos A, Ziras N, Gioulbasanis I, Karampeazis A, Agelidou A, Tsiafaki X, Chandrinos V, Lerikou M, Georgoulias V.

Oncology. 2010;78(3-4):229-36. doi: 10.1159/000315729. Epub 2010 Jun 4.

PMID:
20523083
[PubMed - indexed for MEDLINE]
12.

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.

Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C.

Eur J Cancer. 2010 Mar;46(4):735-43. doi: 10.1016/j.ejca.2009.12.013. Epub 2010 Jan 4.

PMID:
20045311
[PubMed - indexed for MEDLINE]
13.

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.

Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V, Voutsina A.

Lung Cancer. 2010 Jul;69(1):110-5. doi: 10.1016/j.lungcan.2009.09.010. Epub 2009 Oct 24.

PMID:
19854533
[PubMed - indexed for MEDLINE]
14.

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.

Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V.

Br J Cancer. 2009 Aug 18;101(4):589-97. doi: 10.1038/sj.bjc.6605183. Epub 2009 Jul 21.

PMID:
19623181
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.

Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V, Souglakos J.

Clin Cancer Res. 2009 Jun 1;15(11):3827-33. doi: 10.1158/1078-0432.CCR-08-3027. Epub 2009 May 12.

PMID:
19435835
[PubMed - indexed for MEDLINE]
Free Article
16.

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.

Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C.

J Clin Oncol. 2009 Apr 10;27(11):1836-43. doi: 10.1200/JCO.2008.17.5844. Epub 2009 Mar 9.

PMID:
19273711
[PubMed - indexed for MEDLINE]
Free Article
17.

Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.

Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, Mavroudis D, Georgoulias V.

Lung Cancer. 2009 Jan;63(1):77-82. doi: 10.1016/j.lungcan.2008.04.006. Epub 2008 May 27.

PMID:
18508158
[PubMed - indexed for MEDLINE]
18.

Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.

Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group (HORG).

Lung Cancer. 2008 Dec;62(3):356-63. doi: 10.1016/j.lungcan.2008.03.030. Epub 2008 May 22.

PMID:
18501466
[PubMed - indexed for MEDLINE]
19.

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.

Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R.

Br J Cancer. 2008 May 20;98(10):1710-5. doi: 10.1038/sj.bjc.6604344. Epub 2008 Apr 15.

PMID:
18414411
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.

Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D.

Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.

PMID:
17765354
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk